Bosh sahifaCRSP • NASDAQ
add
Crispr Therapeutics AG
48,92 $
Seans yopilganidan keyin:(0,16%)+0,080
49,00 $
Yopilgan:18-okt, 19:47:58 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
48,29 $
Kunlik diapazon
48,40 $ - 49,24 $
Yillik diapazon
37,55 $ - 91,10 $
Bozor kapitalizatsiyasi
4,17 mlrd USD
Oʻrtacha hajm
1,03 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 517,00 ming | -99,26% |
Joriy xarajat | 19,48 mln | 2,36% |
Sof foyda | -126,41 mln | -62,60% |
Sof foyda marjasi | -24,45 ming | -21 915,39% |
Har bir ulushga tushum | -1,49 | -52,04% |
EBITDA | -146,42 mln | -62,21% |
Amaldagi soliq stavkasi | -1,03% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 2,00 mlrd | 13,21% |
Jami aktivlari | 2,34 mlrd | 6,50% |
Jami passivlari | 358,90 mln | -5,80% |
Umumiy kapital | 1,98 mlrd | — |
Tarqatilgan aksiyalar | 85,17 mln | — |
Narxi/balansdagi bahosi | 2,07 | — |
Aktivlardan daromad | -15,83% | — |
Kapitaldan daromad | -16,69% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -126,41 mln | -62,60% |
Operatsiyalardan naqd pul | -95,58 mln | 28,27% |
Sarmoyadan naqd pul | -126,90 mln | -158,50% |
Moliyadan naqd pul | -466,00 ming | -102,78% |
Naqd pulning sof oʻzgarishi | -222,95 mln | -321,91% |
Boʻsh pul | -55,64 mln | 52,07% |
Haqida
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Tashkil etilgan
2013
Bosh ofis
Sayt
Xodimlar soni
407
